© 1992 by Oxford University Press
Journal of the National Cancer Institute, Vol. 84, No. 19, 1486-1491,
October 7, 1992
© 1992 Oxford University Press
Clinical Correlates of MDR1 (P-glycoprotein) Gene Expression in Ovarian and Small-Cell Lung Carcinomas
1Department of Genetics, The University of Illinois Chicago
2University of Texas Health Science Center San Antonio
*Correspondence to: Igor B. Roninson, Ph.D., Department of Genetics (M/C 669), The University of Illinois at Chicago, 808 S. Wood St., Chicago, IL 60612.
Background: Expression of the MDR1 (P-glycoprotein) gene causes resistance to several classes of lipophilic anti-cancer drugs, but MDR1 expression in untreated ovarian and lung carcinomas is rarely detectable by standard assays. Purpose: This study was designed to measure the MDR1 messenger RNA (mRNA) content of ovarian and lung carcinomas and to analyze clinical correlations of MDR1 expression in these tumors. Methods: A sensitive assay based on the polymerase chain reaction (PCR) was used in a retrospective study to measure MDR1 mRNA in biopsy samples of 100 solid tumors, including 60 ovarian and 32 lung carcinomas. The levels of MDR1 mRNA were correlated with history of chemotherapeutic treatment for all tumors; for ovarian and small-cell lung carcinomas (SCLCs), these levels were also correlated with subsequent tumor response to chemotherapy. Results: Among previously untreated patients, MDR1 mRNA was expressed in 68% (50 of 74) of all tumors. Among patients pretreated with chemotherapy regimens that included at least one P-glycoprotein-transported drug (MDR regimens), 95% (20 of 21) of all tumors expressed MDR1 mRNA though the incidence of high-level MDR1 expression was decreased among the treated tumors. MDR1 mRNA was expressed in only one of five tumors treated with regimens that included no P-glycoprotein substrates (non-MDR regimens). Subsequent tumor response to chemotherapy was evaluated in 35 patients with ovarian carcinoma and seven patients with SCLC. The presence of even very low levels of MDR1 mRNA correlated with the lack of response to MDR regimens in these tumor types (P<.035 for ovarian carcinomas, P<.029 for SCLCs, and P<.0005 for both tumor types; Fisher's Exact Test). Conclusions: Low-level expression of MDR1 mRNA correlates with clinical resistance to combination chemotherapy in ovarian cancer and SCLC. We hypothesize that MDR1 is expressed in a sub-population of more malignant tumor cells possessing multiple mechanisms of drug resistance. Implications: The presence of MDR1-expressing tumor cells may be useful as a predictive marker for clinical resistance to combination chemotherapy in ovarian cancer and SCLC. Prospective studies are needed to confirm this hypothesis. [J Natl Cancer Inst 84:1486–1491, 1992]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. W. Sohn, S. Y. Lee, S. J. Lee, E. J. Kim, S. I. Cha, C. H. Kim, J.-T. Lee, T. H. Jung, and J. Y. Park MDR1 Polymorphisms Predict the Response to Etoposide-Cisplatin Combination Chemotherapy in Small Cell Lung Cancer Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 137 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Katahira, T. Takayama, K. Miyanishi, T. Hayashi, T. Ikeda, Y. Takahashi, R. Takimoto, T. Matsunaga, J. Kato, and Y. Niitsu Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin's Lymphoma (Stages III and IV) Clin. Cancer Res., December 1, 2004; 10(23): 7934 - 7940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohishi, Y. Oda, T. Uchiumi, H. Kobayashi, T. Hirakawa, S. Miyamoto, N. Kinukawa, H. Nakano, M. Kuwano, and M. Tsuneyoshi ATP-binding Cassette Superfamily Transporter Gene Expression in Human Primary Ovarian Carcinoma Clin. Cancer Res., December 1, 2002; 8(12): 3767 - 3775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Baekelandt, G. Lehne, C. G. Trope, I. Szanto, P. Pfeiffer, B. Gustavssson, and G. B. Kristensen Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer J. Clin. Oncol., June 15, 2001; 19(12): 2983 - 2993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Advani, G. A. Fisher, B. L. Lum, J. Hausdorff, J. Halsey, M. Litchman, and B. I. Sikic A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance Clin. Cancer Res., May 1, 2001; 7(5): 1221 - 1229. [Abstract] [Full Text]
|
|
|
|
|
|
J. S. Wunder, S. B. Bull, V. Aneliunas, P. D. Lee, A. M. Davis, C. P. Beauchamp, E. U. Conrad, R. J. Grimer, J. H. Healey, M. J. Rock, et al. MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study J. Clin. Oncol., July 14, 2000; 18(14): 2685 - 2694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. C. Dingemans, M. A. Witlox, R. A. L. M. Stallaert, P. van der Valk, P. E. Postmus, and G. Giaccone Expression of DNA Topoisomerase II{{alpha}} and Topoisomerase II{beta} Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer Clin. Cancer Res., August 1, 1999; 5(8): 2048 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chen, G. E. Duran, K. A. Steger, N. J. Lacayo, J.-P. Jaffrezou, C. Dumontet, and B. I. Sikic Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins J. Biol. Chem., February 28, 1997; 272(9): 5974 - 5982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Norris, S. B. Bordow, G. M. Marshall, P. S. Haber, S. L. Cohn, and M. Haber Expression of the Gene for Multidrug-Resistance-Associated Protein and Outcome in Patients with Neuroblastoma N. Engl. J. Med., January 25, 1996; 334(4): 231 - 238. [Abstract] [Full Text] [PDF]
|
|